Tolmupilved

Tolmupilved is a selective serotonin reuptake inhibitor (SSRI) antidepressant medication used to treat major depressive disorder, generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder. It is also indicated for the prevention of migraines in adults. Tolmupilved was approved by the U.S. Food and Drug Administration (FDA) in 2022. The medication is taken orally and is available in tablet form. It is typically prescribed at a starting dose of 100 mg once daily, with the dose adjusted as needed based on the individual's response to treatment. Common side effects of tolmupilved include nausea, diarrhea, dizziness, and sexual dysfunction. Serious side effects may include suicidal thoughts or behaviors, serotonin syndrome, and an increased risk of bleeding. Tolmupilved should be used with caution in patients with a history of seizures, liver disease, or bleeding disorders. It is important to inform healthcare providers about all medications being taken, as tolmupilved may interact with other drugs. Tolmupilved is not recommended for use in patients with known hypersensitivity to the drug or any of its components. As with any medication, it is essential to follow the prescribed dosage and consult a healthcare professional for any concerns or questions regarding its use.